‘Unprecedented’ EMA Response To COVID-19 Must Be Sustained

Post Approval Setting Matters Too, Says New Agency Head Emer Cooke

The agility, flexibility and transparency that the European Medicines Agency has adopted during the development and assessment of COVID-19 products will have to continue after treatments and vaccines are on the market, says the soon-to-be new head of the agency, Emer Cooke.

Antibodies immunoglobulins attacking coronavirus covid-19 influenza virus cell, 3D immune system medical illustration background. Corona virus 2019-ncov sars cell, igm. Coronavirus sars-cov-2 disease
The battle against COVID-19 continues • Source: Shutterstock

The extraordinary way in which the European Medicines Agency is responding to the pandemic will need to be sustained not just for the evaluation of the treatments and vaccines for COVID-19 but also in the post-marketing space.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography